Immunotherapy is one of the four pillars of cancer treatment that has recently emerged as a
beacon of hope for cancer patients. Certain immunotherapies, for example, immune …

Purpose New immuno-oncology therapies targeting programmed cell death receptor 1 (PD-
1) have improved patient outcomes in a broad range of cancers. The objective of this …

Inhibitors of programmed cell death protein 1 (PD-1) and its ligand (PD-L1) have
dramatically changed the treatment landscape for patients with cancer. Clinical activity of …

Abstract Purpose: Sabatolimab (MBG453) and spartalizumab are mAbs that bind T-cell
immunoglobulin domain and mucin domain-3 (TIM-3) and programmed death-1 (PD-1) …

Unlike traditional cancer therapies, such as surgery, radiation and chemotherapy that are
typically non-specific, cancer immunotherapy harnesses the high specificity of a patient's …

The ability of cancer cells to evade the immune system is one of the most deadly
characteristics of the majority of malignant tumours. Accordingly, the recent development of …

Gastrointestinal (GI) cancers are a group of highly aggressive malignancies with a huge
disease burden worldwide. There is clearly a significant unmet need for new drugs and …

Combination immunotherapy with antibodies directed against PD-1 and CTLA-4 shows
improved clinical benefit across cancer indications compared to single agents, albeit with …

Immuno-oncology (IO) is a young and growing field on the frontier of cancer therapy.
Contrary to cancer therapies that directly target malignant cells, IO therapies stimulate the …

Immunostimulatory monoclonal antibodies (mAbs) exert antineoplastic effects by eliciting a
novel or reinstating a pre-existing antitumor immune response. Most often …